within Pharmacolibrary.Drugs.ATC.B;

model B02BD08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.645,
    adminDuration  = 600,
    adminMass      = 0.09,
    adminCount     = 1,
    Vd             = 0.142,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Coagulation factor VIIa (recombinant) is a hemostatic agent used for treatment and prevention of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or IX, congenital factor VII deficiency, Glanzmann's thrombasthenia, and other acquired bleeding disorders. It is approved and widely used in clinical practice, particularly in emergency situations for controlling major bleeding.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers (both sexes), intravenous bolus administration.</p><h4>References</h4><ol><li><p>Mannucci, PM (2015). Half-life extension technologies for haemostatic agents. <i>Thrombosis and haemostasis</i> 113(1) 165–176. DOI:<a href=&quot;https://doi.org/10.1160/TH14-04-0332&quot;>10.1160/TH14-04-0332</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25274414/&quot;>https://pubmed.ncbi.nlm.nih.gov/25274414</a></p></li><li><p>Lindley, CM, Sawyer, WT, Macik, BG, Lusher, J, Harrison, JF, Baird-Cox, K, Birch, K, Glazer, S, &amp; Roberts, HR (1994). Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. <i>Clinical pharmacology and therapeutics</i> 55(6) 638–648. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1994.80&quot;>10.1038/clpt.1994.80</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8004880/&quot;>https://pubmed.ncbi.nlm.nih.gov/8004880</a></p></li><li><p>Mahlangu, J, Levy, H, Kosinova, MV, Khachatryan, H, Korczowski, B, Makhaldiani, L, Iosava, G, Lee, M, &amp; Del Greco, F (2021). Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. <i>Research and practice in thrombosis and haemostasis</i> 5(6) e12576–None. DOI:<a href=&quot;https://doi.org/10.1002/rth2.12576&quot;>10.1002/rth2.12576</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34430790/&quot;>https://pubmed.ncbi.nlm.nih.gov/34430790</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BD08;
